Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Wildner

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Ophthalmic Genetics|October 27, 2020
Retained visual function in a subset of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD)Simon Dulz, Yevgeniya Atiskova, Peter Engel, et al.
Orphanet Journal of Rare Diseases|November 21, 2021
Retinal vessel tortuosity as a prognostic marker for disease severity in Fabry diseaseYevgeniya Atiskova, Jan Wildner, Martin Stephan Spitzer, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|June 2, 2022
Visual perception and macular integrity in non-classical CLN2 diseaseYevgeniya Atiskova, Jan Wildner, Eva Wibbeler, et al.
American Journal of Ophthalmology|March 11, 2026
Retinal Phenotype in Mucopolysaccharidosis Type IIIEmma Sieg, Johannes Birtel, Jan Wildner, et al.
American Journal of Ophthalmology|July 25, 2020
An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 DiseaseSimon Dulz, Yevgeniya Atiskova, Eva Wibbeler, et al.
The British Journal of Ophthalmology|June 30, 2022
Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)Simon Dulz, C Schwering, Jan Wildner, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Ophthalmic Genetics|October 27, 2020
Retained visual function in a subset of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD)Simon Dulz, Yevgeniya Atiskova, Peter Engel, et al.
Orphanet Journal of Rare Diseases|November 21, 2021
Retinal vessel tortuosity as a prognostic marker for disease severity in Fabry diseaseYevgeniya Atiskova, Jan Wildner, Martin Stephan Spitzer, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|June 2, 2022
Visual perception and macular integrity in non-classical CLN2 diseaseYevgeniya Atiskova, Jan Wildner, Eva Wibbeler, et al.
American Journal of Ophthalmology|March 11, 2026
Retinal Phenotype in Mucopolysaccharidosis Type IIIEmma Sieg, Johannes Birtel, Jan Wildner, et al.
American Journal of Ophthalmology|July 25, 2020
An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 DiseaseSimon Dulz, Yevgeniya Atiskova, Eva Wibbeler, et al.
The British Journal of Ophthalmology|June 30, 2022
Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)Simon Dulz, C Schwering, Jan Wildner, et al.
Pageof 1